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Background: There are limited data on the role of adipokines in atopic asthma.
Aim: To determine serum level of apelin-12 (APE-12) in asthmatic children in relation to BMI
and gender.
Methods: Serum APE-12 levels were measured using ELISA in 89 asthmatic children (61 boys
and 28 girls, aged 7.0e17.0 years) and in 33 healthy children. Among examined asthmatics
59 (19 girls and 40 boys) had normal weight and 30 (9 girls and 21 boys) were obese.
Results: The mean serum levels of APE-12 were significantly (p < 0.001) higher both in obese
(174.1  5.9 pg/mL) and non-obese asthmatic children (171.0  4.0 pg/mL) than in healthy
children (130.6  2.1 pg/mL), regardless of gender. No relationships between examined the
adipokine level and asthma severity, spirometric parameters, degree of allergic sensitization,
BMI, BMI-SDS were observed.
Conclusion: Increased serum level of APE-12 suggests that this adipokine may be implicated in
the pathogenesis of childhood atopic asthma.
ª 2012 Elsevier Ltd. All rights reserved.t.pl (A. Kasperska-Zajac).
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Obesity is associated with asthma in both adults and children,
as shown by cross-sectional, caseecontrol, longitudinal, and
weight intervention studies. The exact mechanisms for the
association between obesity and asthma are not known. The
immunologic pathway invokes a possible role for pro-
inflammatory and anti-inflammatory adipokines produced
by adipose tissue.1e5
Although adipose tissue produces over 50 adipokines, most
reports concentrated on the role of pro-inflammatory leptin
and anti-inflammatory adiponectin, which may affect
asthma. However, recent data are inconclusive regarding the
independent associationbetween serum leptin or adiponectin
and the risk of asthma.6e8 Some findings suggest that leptin
and adiponectin might be involved in the causal pathway
between obesity and allergic sensitization and asthma in
humans,6,7 but other studies do not confirm this hypothesis.5
It has been suggested that another adipokine, resistin,
play a role in asthma pathogenesis and severity in adults.9
Conversely, studies in children suggest that resistin may
reduce risk of asthma.10 Hence, it seems that other adi-
pokines should be additionally explored in relation to
asthma risk and asthma severity.5
Apelin (APE) is a bioactive peptide identified as the
endogenous ligand of the previously discovered “orphan”
receptor named APJ, isolated by Tatemoto et al. from
bovine stomach extracts in 1998.11 Several different iso-
forms of APE have been identified. The predominant form
of circulating APE is believed to be APE-36. However, also
shorter C-terminal fragments with biological activity have
been found, including APE-17, APE-16, APE-13 and APE-
12.12,13 It has been demonstrated that the biological
activity of APEs is related inversely to the peptide length :
thus, APE-12 is the most potent isoform. However, APE-11
and shorter peptides are inactive.14
APE belongs to the adipokines group because its mRNA
expression has been demonstrated in mature adipocytes
and vascular stroma of fat tissue.15,16 APE peptide expres-
sion has been also detected in other tissues, including brain
cells, gastrointestinal tract, and osteoblasts.17,18 APE and
its receptor APJ constitute a signaling pathway best
recognized as an important regulator of cardiovascular
homeostasis.19 APE suppresses the production of proin-
flammatory cytokines20 and chemotactic activity.21 This
multifunctional apelinergic system is also highly expressed
in pulmonary tissue, including bronchial and alveolar
epithelial cells, and small pulmonary blood vessels.22e24
The apelinergic system distribution over such a variety of
tissues has suggested that it might play relevant roles in
humanphysiology. Thepotential association between asthma
and apelin has not been explored so far and remains obscure.
Thus, theaimof our studywas toanalyze apelin serum level in
children with allergic asthma in relation to BMI and gender.
Comparison between serum levels of APE-12 in distinguishing
childrenwithatopicasthmafromhealthywasalsoperformed.
Material and methods
The study group was comprised of randomly selected atopic
asthma patients from320 asthmaticswho consecutive visitedallergy outpatient clinics in Department Pediatric Silesian
University of Medicine between January 2010 to December
2010. The studywas approved by the Ethics Committee of the
Medical University of Silesia in Katowice and written
informed consent was obtained from children’s parents.
Finally 89 children (61 boys and 28 girls, aged 7.0e17.0
years; mean age 11.34  0.37 years) with stable atopic
asthmawereenrolled into study. Thediagnosis of asthma, the
assessment of severity, asthmamanagement plan andasthma
control level were established according to the GINA 2006
criteria.25 Twelve children had intermittent, 56 had mild
disease, and 32 had moderate persistent asthma. Children
with severe asthma and asthmaexacerbationswere excluded
from the study. Duration of the diseases ranged from 2 years
to 6 years. During control visit children underwent spiro-
metric assessment using LUNG TEST 1000 device (Poland) as
previouselly described in details.26 All asthmatic children had
positive skin prick tests (SPTs) to1 allergens. A positive SPT
was defined as a mean diameter of at least 3 mm in the
presence of negative diluent and positive histamine controls.
The degree of allergic sensitization was measured by the
wheal size of SPTs.
All children had stable, well controlled asthma accord-
ing to GINA 2006 criteria and no changes were made in
chronic anti-inflammatory treatment within the previous 12
weeks. None of the patients reported respiratory tract or
other infections at least 3 month prior to the study.
Seventy-six children with mild or moderate asthma were
treated with regularly inhaled corticosteroids (ICS) at
a variable daily dose required to control disease symptoms.
At the time of evaluation, daily ICS doses ranged from 100
to 600 mg/day (mean daily dose: 246.76  16.70 mg/day).
The control group consisted of 33 healthy children (20
boys and 13 girls) with normal weight matched for sex and
age (aged 7.0e17.0 years; mean age 11.71  3.79 years).
Controls had negative history of allergic diseases with
negative SPT results to a panel of aeroallergens (dust mite,
mixed grass, or tree pollen; cat and dog; Allergopharma,
Reinbek, Germany) and had normal level of total serum
immunoglobulin (IgE). These control children without
evidence of pulmonary or systemic inflammatory disease
attended the outpatient pediatric clinic for non-
immunological and non-inflammatory problems and they
needed venous puncture.
Anthropometric measurements
Body mass index (BMI) (body weight [kg] divided by height
[m2] and standard deviation [SD] score for BMI (BMI-SDS)
were calculated according to current Polish populational
predicted values.27 BMI-SDS was calculated according to
formula: [current patient’s BMI (kg/m2) e BMI equal to 50th
percentile (kg/m2)/[BMI equal to 50th percentile (kg/m2)-
BMI equal to 3rd percentile (kg/m2)]. Normal weight was
defined as BMI-SDS between 2.0 and þ2.0. Obesity was
defined as BMI-SDS >2.0.
Laboratory assays
Blood samples for analyses were collected in the fasting
state between 07:00 AM and 09; 30 AM.
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previously described,28 using commercial human APE-12
enzyme immunoassay kits (Phoenix Pharmaceuticals Inc.,
Burlingame, CA) following the manufacturer’s instructions.
Before the assay, serum samples were extracted to isolate
analyzed peptides before assay. Buffer A (1% trifluoroacetic
acid aqueous solution), buffer B (60% acetonitrile solution
in 1% trifluoroacetic acid solution), and SEP-PAK C chro-
matographic columns (Waters Associates, Milford, MA) were
used for extraction. The obtained extract was lyophilized
and then dissolved in the assay buffer before analysis. The
absorbance measurements for all samples were performed
using the Quant Universal Microplate Spectrophotometer
(BioTek Instruments Inc., Winooski, VT, USA) at 450 nm
wavelengths. The sensitivity was 0.07 pg/mL for APE-12 kit;
the intraassay coefficient of variance was 5% or less, and
the extraassay coefficient of variance was 14%.
Statistical analysis
Statistical analysis was performed using Statistica 6.0
software (StatSoft Inc., Tulsa, OK). Normal data distribution
was assessed using ShapiroeWilk test, and the homogeneity
of variance was assessed using Levene’s test. Comparisons
between the examined groups were performed using the
ANOVA and post hoc RIR Tukey’s multiple comparison test
for different sample sizes or KruskaleWallis test if data
distribution was not normal. Correlations were analyzed by
Spearman’s test if data distribution was not normal. All
results were considered statistically significant at p < 0.05.
Results
Characteristics of the 89 subjects with asthma and the 33
healthy control subjects are presented in Table 1. Both
groups were similar with regard to age and sex. Among
studied asthma children 30 (9 girls and 21 boys) were obese
(AO) and 59 (19 girls and 40 boys) had normal weigh, normal
BMI and BMI-SDS within range of 2 to þ2 (ANW). Obese
asthmatic children (both girls and boys) had significantly
higher (p < 0.001) BMI and BMI-SDS than healthy controls
(boys and girls with BMI-SD within range 2 to þ2). Asthma
was well controlled in studied children and the mean values
of FEV1 and FVC in asthmatics did not differ from mean
values obtained from control group. Mean values of IgE
concentrations in all asthmatic children (both in AO and
ANW) were significantly higher than in controls (p < 0.01).
The mean values of APE-12 serum levels in all children
are shown in Table 2. The mean serum levels of APE-12
were significantly (p < 0.001) higher both in obese
(174.1  5.9 pg/mL) and non-obese asthmatic children
(171.0  4.0 pg/mL) than in healthy children
(130.6  2.1 pg/mL) regardless of gender. After stratifying
by gender, there was a significant higher mean APE-12
concentration (P < 0.0 01) in AO girls (188.9  8.0 pg/
mL) and ANW girls (186. 2  5.9 pg/mL) compared to girls
from control group (134.4  1.8 pg/mL). In AO boys and
ANW boys also significantly higher (p < 0.01) mean values of
APE-12 (167.8  5.9 pg/mL and 163.9  3.5 pg/mL
respectively) were observed than in control boys
(124.8  1.7 pg/mL).The mean APE-12 levels obtained in girls with asthma
were significantly higher than in boys with asthma
(P < 0.001, P < 001, respectively). In the control group,
serum levels of APE-12 did not differ significantly between
girls and boys (Table 2).
No significantly relationships between APE-12 levels and
BMI or BMI-SDS were noticed in asthmatic and healthy
children (data not shown).
The serum IgE levels correlated with a degree of sensi-
tization measured by wheal size of SPTs (r: 0.45,
PZ 0.005). We did not find any correlation between APE-12
levels and lung function tests, allergic sensitization as well
as severity of asthma (data not shown).Discussion
In the present study we provided evidence that in asth-
matic children, irrespective to BMI, serum profile of apelin
(APE-12) is different from healthy ones. To best our
knowledge for the first time we have demonstrated that
APE-12 serum levels are increased in asthmatic children.
However no relationships between serum apelin levels and
allergic sensitization were found.
The origin of blood apelin and the regulations of its input
into the bloodstream remain a subject of interest. One
source of the plasma apelin may be overspill from the
vascular and endothelial cells, but it also has been
demonstrated that apelin is expressed and secreted by both
human and mouse adipocytes. Apelin synthesis in adipo-
cytes is stimulated by insulin, and plasma apelin level
markedly increases in obesity associated with insulin
resistance and hyperinsulinemia.15 Thus, increased apelin
expression in adipose tissue could contribute to apelin
plasma levels. Well known pro-inflammatory cytokine
tumor necrosis factor-alpha (TNF-a), that has been impli-
cated in many aspects of the airway pathology in asthma,29
may act as a direct up-regulator of apelin expression in
adipocytes in both obese and lean humans. TNF-a increases
significantly apelin plasma levels when administered to
mice by intraperitoneal injection.30
The origin and the role of increased apelin levels in the
serum of examined children with allergic asthma remain
unclear. To date, there are no reports about the eventual
influences of apelin on bronchial smooth muscle, bronchial
contractility or hyperreactivity, or its potential role in
allergic inflammation. In the human lungs APJ-LI was
restricted to endothelial cells of small pulmonary vessels
and lower levels to vascular smooth muscle of pulmonary
vessels.22 Nevertheless recently, Feng et al23 noticed
significantly elevated apelin expression in the bronchial
epithelium after induction of acute pulmonary embolism in
dogs. Apelin had also beneficial effect in neonatal rats with
hyperoxia induced lung injury. Prophylactic apelin admin-
istration improved alveolarisation, reduced pulmonary
fibrin deposition, inflammation and septum thickness via
a nitric oxide synthase-dependent mechanism.24 If apelin
has some beneficial effect in human asthma and if increased
apelin plasma levels may be the defense mechanisms in
childhood asthma are subjects of speculations and need
further explorations. It is assumed that the overproduction
of apelin in obesity could be a protective mechanism before
Table 1 Demographic characteristic in asthma and healthy children.
Asthmatics with normal weight N Z 59
ANW
(19 girls, 40 boys)
Asthmatics with obesity N Z 30
AO
(9 girls, 21 boys)
Healthy controls N Z 33
H
(13 girls, 20 boys)
Age [years]
Girls 12.4  0.6 (12.0, 4.5) 12.4  2.6 (12.0, 7.5) 13.5  1.2 (14.2, 3.7)
Boys 11.8  0.5 (12.5, 5.7) 11.7  1.3 (12.0, 3.0) 11.8  1.6 (11.0, 4.0)
All 12.0  0.82 (12.5, 4.6) 11.9  1.2 (12.7, 6.0) 12.9  1.0 (13.0, 4.0)
BMI [kg/m2]
Girls 18.2  1.15 (18.9, 4.1) 23.4  2.0 (23.8, 5.1) b 18.8  0.9 (19.1, 3.0)
Boys 18.4  0.72 (18.3, 4.1) 25.2  1.8 (25.8, 5.0) c 17.3  1.1 (16.8, 2.4)
Total 18.3  0.61 (18.3, 3.9) 24.6  1.4 (24.8, 4.8) c 18.3  0.8 (18.0, 3.0)
BMI-SDS
Girls 0.01  0.52 (0.0, 2.3) 3.14  0.54 (3.05, 1.4) c 0.19  0.42 (0.1, 1.3)
Boys 0.15  0.27 (0.09, 1.24) 4.49  0.91 (4.18, 3.1) c 0.46  0.58 (0.83, 1.93)
Total 0.11  0.25 (0.08, 1.57) 4.09  0.69 (3.78, 3.07) c 0.29  0.34 (0.11, 1.87)
FEV1 [% predicted]
Girls 87.3  9.28 (87.0, 32.0) 95.8  6.8 (98.0, 10.0) 98.7  5.8 (102.0, 15.5)
Boys 87.2  4.22 (85.0, 19.0) 93.3  8.19 (100.0, 21.0) 90.8  11.9 (87.5, 31.7)
Total 87.2  4.1(85.0, 23.0) 94.1  5.9 (99.5, 20.0) 96.06  5.62 (98.0, 19.0)
FVC [% predicted]
Girls 89.29  6.92 (88.0, 15.0) 96.1  5.2 (96.0, 11.0) 97.6  7.7 (99.0, 23.5)
Boys 90.5  4.11 (90.1, 16.0) 93.9  6.7 (98.0, 22.0) 93.2  11.4 (95.6, 24.0)
Total 89.8  3.5 (88.5, 16.0) 94.6  4.8 (96.5, 15.5) 96.3  6.3 (99.0, 20.0)
IgE [IU/mL]
Girls 485.1  269.3 (284.4, 503.0) 414.4  344.4 (248.8, 292.0) 70.5  39.4 (32.7, 115.7)
Boys 355.7  105.8 (272.5, 402.3) 415.2  161.4 (393.7, 396.0) 24.3  16.2 (16.8, 31.7)
Total 398.6  111.3 (280.0, 384.5) a 414.9  150.7 (329.0, 404.0) a 50.7  25.2 (30.0, 60.7)
Data are shown as: mean  1.96 SE (median, IQR i.e the interquartile range i.e. difference between the upper and lower quartiles).
a p < 0.01 in comparison with control group.
b p Z 0.02 in comparison with control group and vs asthmatics with normal weight.
c p < 0.001 in comparison with control group and vs asthmatics with normal weight.
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cardiovascular dysfunction.13 DeVisser et al.24 conclude that
results of their recent study suggest the potential role of
apelin administration for therapeutic intervention in
humans suffering from chronic obstructive pulmonary
disease or asthma. In the cardiovascular system apelin
elicits endothelium-dependent, nitric oxide-mediated vas-
orelaxation and reduces arterial blood pressure.14 Addi-
tionally apelin demonstrates potent and long-lasting
positive inotropic activity being one of the most potent
endogenous stimulators of cardiac contractility.31
In our study we found no linear relationsip between BMI
and apelin. Recently Reinehr et al32 find a lack of associationTable 2 APE-12 serum concentration in asthmatic and healthy
Asthmatics with normal weight N Z 59
ANW
(19 girls, 40 boys)
Asth
AO
(9 g
Apelin (pg/mL)
Girls 186.2  5.9 (188.0, 18.0)a,b 188.
Boys 163.9  3.5 (166.0, 13.0) a 167.
All 171.0  4.0 (170.0, 20.0) a 174.
Data are shown as: mean  1.96 SE (median, IQR i.e the interquartil
a p < 0.001 in comparison with control group.
b <0.001 girls vs boys.between apelin, insulin resistance, cardiovascular risk
factors, and obesity in children. In Reinher et. al study
apelin levels did not differ significantly between obese and
lean children. Additionaly apelin concentrations were not
signiffcantly related to age, gender, pubertal stage, SDS-
BMI, body fat leptin. Also weigh loss in obese children was
not associated with a change in apelin concentrations. In our
previous study28 APE-12 concentrations were related to BMI,
but in larger group comprising 4 subgroups: girls (but not
boys) with anorexia nervosa, girls with no otherwise speci-
fied eating disorders, healthy girls, and obese girls.
A possible limitation of our study was that it included
children from a wide age range. Lack of subjects withchildren.
matics with obesity N Z 30
irls, 21 boys)
Healthy controls N Z 33
H
(13 girls, 20 boys)
9  8.0 (192.0, 16.0)a,b 134.4  1.8 (135.6, 5.8)
8  5.9 (168.0, 8.0) a 124.8  1.7 (123.5, 2.6)
1  5.9 (170.0, 20.0)a 130.6  2.1(131.1, 10.6)
e range i.e. difference between the upper and lower quartiles).
200 E. Machura et al.severe asthma and exacerbation of asthma may also be
a drawback of this study. In our study only children with
atopic asthma, but not with non-atopic asthma, were
investigated. So we can’t state with certainty whether
elevated serum apelin levels are characteristic for asthma
itself or if this finding reflects at least partially atopic status
per se. Another limitation of the study was gender bias.
Atopic asthma is more prevalent in prepubescent and
adolescent boys than in girls, so it was not surprising that in
our cohort boys outnumbered girls. However, our study was
performed on a specialty clinic sample to minimize the
likelihood that children without asthma would be included,
and to ensure that consecutive patients who visited allergy
outpatient clinics would be enrolled. We did not estimate
the BAL-conentration of apelin.
Conclusions
In atopic childhood asthma, increased apelin (APE-12)
levels were observed independent of obesity. These find-
ings suggest the potential association between apelin and
atopic asthma. However, APE-12 has limited value as
potential biomarker in estimation of atopic asthma severity
and degree of allergic sensitization.
Although this was a cross-sectional study with a rela-
tively small sample size, we believe that our data may be
a basis for further studies evaluating the possible role of
adipokines in childhood atopic asthma pathogenesis.
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